Latest Insider Transactions at Dicerna Pharmaceuticals Inc (DRNA)
This section provides a real-time view of insider transactions for Dicerna Pharmaceuticals Inc (DRNA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Dicerna Pharmaceuticals Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Dicerna Pharmaceuticals Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 05
2021
|
James B Weissman Chief Operating Officer & EVP |
SELL
Open market or private sale
|
Direct |
7,156
-25.5%
|
$186,056
$26.99 P/Share
|
|
Feb 03
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Open market or private sale
|
Direct |
8,312
-27.87%
|
$207,800
$25.0 P/Share
|
|
Feb 03
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,312
+21.79%
|
$74,808
$9.09 P/Share
|
|
Feb 02
2021
|
Regina M. Paglia Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
4,431
-100.0%
|
$106,344
$24.0 P/Share
|
|
Feb 02
2021
|
Regina M. Paglia Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,431
+50.0%
|
$53,172
$12.93 P/Share
|
|
Jan 25
2021
|
Regina M. Paglia Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
6,326
-100.0%
|
$158,150
$25.0 P/Share
|
|
Jan 25
2021
|
Regina M. Paglia Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,431
+41.19%
|
$53,172
$12.93 P/Share
|
|
Jan 25
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Open market or private sale
|
Direct |
21,630
-50.13%
|
$540,750
$25.0 P/Share
|
|
Jan 25
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
16,630
+27.82%
|
$149,670
$9.09 P/Share
|
|
Jan 12
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Open market or private sale
|
Direct |
5,808
-17.97%
|
$139,392
$24.07 P/Share
|
|
Jan 12
2021
|
James B Weissman Chief Operating Officer & EVP |
SELL
Open market or private sale
|
Direct |
5,808
-17.15%
|
$139,392
$24.08 P/Share
|
|
Jan 11
2021
|
James B Weissman Chief Operating Officer & EVP |
SELL
Open market or private sale
|
Direct |
3,800
-10.09%
|
$87,400
$23.99 P/Share
|
|
Jan 08
2021
|
Robert D. Ciappenelli Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,002
-34.67%
|
$46,046
$23.29 P/Share
|
|
Jan 08
2021
|
Robert D. Ciappenelli Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,775
+50.0%
|
-
|
|
Jan 08
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
2,842
-8.08%
|
$65,366
$23.29 P/Share
|
|
Jan 08
2021
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,650
+19.74%
|
-
|
|
Jan 08
2021
|
Regina M. Paglia Chief Human Resources Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,005
-34.66%
|
$23,115
$23.29 P/Share
|
|
Jan 08
2021
|
Regina M. Paglia Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,900
+50.0%
|
-
|
|
Jan 08
2021
|
Douglas Fambrough Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,159
-14.26%
|
$141,657
$23.29 P/Share
|
|
Jan 08
2021
|
Douglas Fambrough Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,950
+31.6%
|
-
|
|
Jan 08
2021
|
James B Weissman Chief Operating Officer & EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
2,842
-7.02%
|
$65,366
$23.29 P/Share
|
|
Jan 08
2021
|
James B Weissman Chief Operating Officer & EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
8,650
+17.6%
|
-
|
|
Dec 10
2020
|
Adam Koppel Director |
SELL
Open market or private sale
|
Indirect |
1,000,000
-24.51%
|
$23,000,000
$23.4 P/Share
|
|
Dec 01
2020
|
James B Weissman Chief Operating Officer & EVP |
SELL
Open market or private sale
|
Direct |
4,360
-12.04%
|
$109,000
$25.21 P/Share
|
|
Dec 01
2020
|
James B Weissman Chief Operating Officer & EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
4,360
+10.74%
|
$13,080
$3.42 P/Share
|
|
Dec 01
2020
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Open market or private sale
|
Direct |
8,185
-23.59%
|
$204,625
$25.19 P/Share
|
|
Dec 01
2020
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,185
+19.09%
|
$24,555
$3.42 P/Share
|
|
Nov 04
2020
|
Regina M. Paglia Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
30,000
-75.0%
|
$660,000
$22.75 P/Share
|
|
Nov 04
2020
|
Regina M. Paglia Chief Human Resources Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+50.0%
|
$360,000
$12.93 P/Share
|
|
Nov 02
2020
|
James B Weissman Chief Operating Officer & EVP |
SELL
Open market or private sale
|
Direct |
4,360
-12.04%
|
$87,200
$20.95 P/Share
|
|
Nov 02
2020
|
James B Weissman Chief Operating Officer & EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
4,360
+10.74%
|
$13,080
$3.42 P/Share
|
|
Nov 02
2020
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Open market or private sale
|
Direct |
8,185
-23.59%
|
$171,885
$21.03 P/Share
|
|
Nov 02
2020
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,185
+19.09%
|
$24,555
$3.42 P/Share
|
|
Oct 20
2020
|
James B Weissman Chief Operating Officer & EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+23.89%
|
$20,000
$2.97 P/Share
|
|
Oct 16
2020
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
SELL
Open market or private sale
|
Direct |
16,370
-38.17%
|
$343,770
$21.0 P/Share
|
|
Oct 16
2020
|
Bob D Brown Chief Scientific Ofr., EVP R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
16,370
+27.63%
|
$49,110
$3.42 P/Share
|
|
Oct 15
2020
|
James B Weissman Chief Operating Officer & EVP |
SELL
Open market or private sale
|
Direct |
8,720
-28.52%
|
$174,400
$20.2 P/Share
|
|
Oct 15
2020
|
James B Weissman Chief Operating Officer & EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
8,720
+22.19%
|
$26,160
$3.42 P/Share
|
|
Nov 19
2019
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,750,000
-23.87%
|
$38,500,000
$22.03 P/Share
|
|
May 29
2019
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,600,000
-17.92%
|
$19,200,000
$12.5 P/Share
|
|
Dec 18
2017
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Indirect |
2,645,442
+34.27%
|
-
|
|
Dec 18
2017
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
190,849
+2.09%
|
-
|
|
Dec 18
2017
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Indirect |
8,454,388
+49.17%
|
-
|
|
Dec 18
2017
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
285,000
+50.0%
|
$1,995,000
$7.0 P/Share
|